Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093834 | 1.00 | SSTR4 (0.44) | SSTR4RENALOX5EPHX2CYP2D6 | |
| SCHEMBL4106036 | 1.00 | SSTR4 (0.44) | SSTR4RENALOX5EPHX2CYP2D6 | |
| SCHEMBL4094874 | 1.00 | SSTR4 (0.44) | SSTR4RENALOX5EPHX2CYP2D6 | |
| SCHEMBL4067653 | 0.91 | SSTR4 (0.41) | SSTR4CYP2D6 | |
| SCHEMBL3579316 | 0.91 | SSTR4 (0.41) | SSTR4CYP2D6 | |
| SCHEMBL16274994 | 0.87 | REN (0.40) | SSTR4RENEPHX2 | |
| SCHEMBL4106508 | 0.85 | REN (0.47) | SSTR4RENEPHX2 | |
| SCHEMBL4099323 | 0.85 | REN (0.47) | SSTR4RENEPHX2 | |
| SCHEMBL3570815 | 0.83 | RPS6KB1 (0.38) | SSTR4CCR5 | |
| SCHEMBL3576110 | 0.83 | CCR5 (0.38) | SSTR4CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | SSTR4 291/4885REN 6/4885ALOX5 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.